For additional information on GSK's Oncology portfolio or the data being presented at ASCO, including detailed product fact sheets and press releases, visit http://www.gsk.com/media. This information will be updated throughout the ASCO annual meeting. Please also see onsite contact information listed at the end of this release.
TYKERB is an oral small-molecule inhibitor of the HER2 tyrosine kinase receptor. Stimulation of HER2 is associated with cell proliferation and with multiple processes involved in tumor progression and metastases. Overexpression of this receptor has been reported in a variety of human tumors and is associated with poor prognosis and reduced overall survival.
On March 13, 2007, the United States Food and Drug Administration (FDA) approved TYKERB, in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. TYVERB recently received a positive opinion from the Committee for Medical Products for Human Use (CHMP) of Europe. Marketing authorization in Europe is pending.
GSK in Oncology
GSK Oncology is dedicated to producing innovations in cancer that will
make profound differences in the lives of patients. Through GSK's
revolutionary 'bench to bedside' approach, we are transforming the way
treatments are discovered and developed, resulting in one of the most
robust pipelines in the oncology sector. Our worldwide research in oncology
includes collaborations with more than 160 cancer centers. GSK is closing
in on cancer from all sides with a new generation of patient focused cancer
treatments in p
Copyright©2008 PR Newswire.
All rights reserved